TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

Additionally, as TransMedics plans to enter the dynamic cold perfusion market in the second half of 2025, it may face more direct competition from established players like XVIVO. This increased ...

The crucial limitation in paediatric cardiac donation in DCD has been technological, as the currently approved ex situ mechanical perfusion device (TransMedics OCS Heart ... child DCD heart recovery.

Additionally, as TransMedics plans to enter the dynamic cold perfusion market in the second half of 2025, it may face more direct competition from established players like XVIVO. This increased ...

BURLINGAME, CA, UNITED STATES, January 14, 2025 /EINPresswire / -- The Perfusion System Market Report is the result of extensive research and analysis conducted by our team of experienced market ...

paints a grim picture of TransMedics' business practices. The report's allegations center on the company's warm perfusion technology platform, known as the Organ Care System (OCS), and its ...

Deep-pocketed investors have adopted a bullish approach towards TransMedics ... Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion ...

The report further alleges that TransMedics has been involved in kickbacks, billing fraud, unreported device failures, and widespread off-label misuse of its Organ Care System (OCS). In response ...

TransMedics has developed a new type of organ transplant technology called the Organ Care System (OCS), which provides oxygen and nutrients to organs during transport. This new technology aims to ...

I will reiterate in the sentences that follow. For starters, TransMedics' extracorporeal warm perfusion [EWP] boxes are not innovative nor is TransMedics the only EWP provider in the U.S. While ...